| Schedule of disaggregation of revenue |
The following table summarizes our revenue recognized in our consolidated condensed statements of operations: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2023 | | 2022 | | 2023 | | 2022 | | Net product revenue | $ | 6,979.8 | | | $ | 5,870.9 | | | $ | 13,218.0 | | | $ | 13,003.8 | | Collaboration and other revenue(1) | 1,332.3 | | | 617.1 | | | 2,054.1 | | | 1,294.2 | | | Revenue | $ | 8,312.1 | | | $ | 6,488.0 | | | $ | 15,272.1 | | | $ | 14,298.0 | |
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $30.3 million and $55.4 million during the three and six months ended June 30, 2023, respectively, and $34.4 million and $87.6 million during the three and six months ended June 30, 2022, respectively. The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended June 30, 2023 and 2022: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | | 2023 | | 2022 | | U.S. | Outside U.S. | Total | | U.S. | Outside U.S. | Total | | | | | | | | | | Diabetes: | | | | | | | | Trulicity® | $ | 1,371.3 | | $ | 441.2 | | $ | 1,812.5 | | | $ | 1,430.1 | | $ | 481.7 | | $ | 1,911.9 | | Mounjaro® | 915.7 | | 64.0 | | 979.7 | | | 12.6 | | 3.4 | | 16.0 | | Jardiance(1) | 386.1 | | 282.2 | | 668.3 | | | 250.7 | | 210.3 | | 461.0 | | | Baqsimi | 606.2 | | 7.7 | | 613.9 | | | 21.8 | | 7.2 | | 29.0 | | Humalog® (2) | 229.8 | | 210.6 | | 440.4 | | | 238.8 | | 208.3 | | 447.1 | | Humulin® | 144.3 | | 61.0 | | 205.3 | | | 202.3 | | 71.7 | | 274.0 | | Basaglar® (3) | 83.0 | | 71.2 | | 154.2 | | | 95.8 | | 78.4 | | 174.2 | | | Other diabetes | 45.0 | | 91.6 | | 136.6 | | | 40.1 | | 85.0 | | 125.0 | | | Total diabetes | 3,781.4 | | 1,229.5 | | 5,010.9 | | | 2,292.2 | | 1,146.0 | | 3,438.2 | | | | | | | | | | | Oncology: | | | | | | | | Verzenio® | 588.6 | | 338.2 | | 926.8 | | | 384.3 | | 204.2 | | 588.5 | | Cyramza® | 115.0 | | 145.3 | | 260.3 | | | 92.6 | | 138.6 | | 231.3 | | Erbitux® | 145.5 | | 17.0 | | 162.5 | | | 125.1 | | 15.7 | | 140.8 | | Alimta® | 17.9 | | 43.1 | | 60.9 | | | 171.7 | | 56.1 | | 227.7 | | | Other oncology | 68.0 | | 192.4 | | 260.5 | | | 45.3 | | 135.2 | | 180.4 | | | Total oncology | 935.0 | | 736.0 | | 1,671.0 | | | 819.0 | | 549.8 | | 1,368.7 | | | | | | | | | | | Immunology: | | | | | | | | Taltz® | 472.3 | | 231.6 | | 703.9 | | | 411.6 | | 194.7 | | 606.2 | | Olumiant® (4) | 50.8 | | 168.1 | | 218.9 | | | 10.4 | | 175.8 | | 186.2 | | | Other immunology | — | | 5.7 | | 5.7 | | | — | | 4.0 | | 4.0 | | | Total immunology | 523.1 | | 405.4 | | 928.5 | | | 422.0 | | 374.5 | | 796.5 | | | | | | | | | | | Neuroscience: | | | | | | | | Emgality® | 118.8 | | 50.5 | | 169.3 | | | 108.6 | | 48.9 | | 157.5 | | | | | | | | | | | Other neuroscience | 42.1 | | 175.8 | | 217.9 | | | 36.2 | | 196.3 | | 232.4 | | | Total neuroscience | 160.9 | | 226.3 | | 387.2 | | | 144.8 | | 245.2 | | 389.9 | | | | | | | | | | | | | | | | | | | Other: | | | | | | | | Forteo® | 97.4 | | 50.6 | | 148.0 | | | 78.5 | | 60.0 | | 138.5 | | Cialis® | 9.2 | | 106.4 | | 115.6 | | | 10.8 | | 136.2 | | 147.0 | | COVID-19 antibodies(5) | — | | — | | — | | | 129.1 | | — | | 129.1 | | | Other | 24.4 | | 26.5 | | 51.0 | | | 38.5 | | 41.7 | | 80.1 | | | Total other | 131.0 | | 183.5 | | 314.6 | | | 256.9 | | 237.9 | | 494.7 | | | Revenue | $ | 5,531.4 | | $ | 2,780.7 | | $ | 8,312.1 | | | $ | 3,934.8 | | $ | 2,553.3 | | $ | 6,488.0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR. (2) Humalog revenue includes insulin lispro. (3) Basaglar revenue includes Rezvoglar®. (4) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations. (5) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the six months ended June 30, 2023 and 2022: | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, | | | 2023 | | 2022 | | U.S. | Outside U.S. | Total | | U.S. | Outside U.S. | Total | | | | | | | | | | Diabetes: | | | | | | | | | Trulicity | $ | 2,918.7 | | $ | 871.0 | | $ | 3,789.6 | | | $ | 2,744.1 | | $ | 909.1 | | $ | 3,653.2 | | | Mounjaro | 1,452.2 | | 96.0 | | 1,548.2 | | | 12.6 | | 3.4 | | 16.0 | | Jardiance(1) | 715.6 | | 530.2 | | 1,245.8 | | | 480.4 | | 400.0 | | 880.4 | | Humalog(2) | 501.4 | | 400.0 | | 901.4 | | | 607.7 | | 457.6 | | 1,065.3 | | | Baqsimi | 629.3 | | 16.1 | | 645.4 | | | 44.3 | | 13.9 | | 58.2 | | | Humulin | 343.1 | | 114.2 | | 457.3 | | | 392.8 | | 154.5 | | 547.2 | | Basaglar(3) | 218.4 | | 145.2 | | 363.5 | | | 215.1 | | 150.6 | | 365.7 | | | Other diabetes | 77.7 | | 172.2 | | 250.1 | | | 71.7 | | 168.5 | | 240.3 | | | Total diabetes | 6,856.4 | | 2,344.9 | | 9,201.3 | | | 4,568.7 | | 2,257.6 | | 6,826.3 | | | | | | | | | | | Oncology: | | | | | | | | | Verzenio | 1,049.6 | | 628.0 | | 1,677.7 | | | 685.7 | | 372.1 | | 1,057.9 | | | Cyramza | 215.6 | | 281.4 | | 497.0 | | | 171.8 | | 289.7 | | 461.5 | | | Erbitux | 264.2 | | 28.1 | | 292.4 | | | 234.7 | | 28.7 | | 263.4 | | | Alimta | 38.0 | | 81.2 | | 119.1 | | | 425.9 | | 145.8 | | 571.7 | | | Other oncology | 121.0 | | 319.9 | | 440.8 | | | 84.6 | | 282.7 | | 367.2 | | | Total oncology | 1,688.4 | | 1,338.6 | | 3,027.0 | | | 1,602.7 | | 1,119.0 | | 2,721.7 | | | | | | | | | | | Immunology: | | | | | | | | | Taltz | 784.5 | | 446.3 | | 1,230.8 | | | 718.8 | | 375.5 | | 1,094.3 | | Olumiant(4) | 93.1 | | 354.6 | | 447.8 | | | 81.7 | | 360.1 | | 441.8 | | | Other immunology | — | | 27.7 | | 27.7 | | | — | | 8.5 | | 8.5 | | | Total immunology | 877.6 | | 828.6 | | 1,706.3 | | | 800.5 | | 744.1 | | 1,544.6 | | | | | | | | | | | Neuroscience: | | | | | | | | | Emgality | 227.5 | | 96.1 | | 323.6 | | | 216.9 | | 89.8 | | 306.7 | | | | | | | | | | | Other neuroscience | 77.9 | | 346.2 | | 424.1 | | | 81.2 | | 399.7 | | 481.0 | | | Total neuroscience | 305.4 | | 442.3 | | 747.7 | | | 298.1 | | 489.5 | | 787.7 | | | | | | | | | | | Other: | | | | | | | | | Forteo | 168.0 | | 102.3 | | 270.3 | | | 148.7 | | 127.2 | | 275.9 | | | Cialis | 16.8 | | 199.1 | | 215.9 | | | 17.7 | | 347.0 | | 364.7 | | COVID-19 antibodies(5) | — | | — | | — | | | 1,584.3 | | 14.7 | | 1,598.9 | | | Other | 55.0 | | 48.7 | | 103.7 | | | 88.5 | | 89.6 | | 178.2 | | | Total other | 239.8 | | 350.1 | | 589.9 | | | 1,839.2 | | 578.5 | | 2,417.7 | | | Revenue | $ | 9,967.6 | | $ | 5,304.6 | | $ | 15,272.1 | | | $ | 9,109.4 | | $ | 5,188.7 | | $ | 14,298.0 | |
Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog revenue includes insulin lispro. (3) Basaglar revenue includes Rezvoglar. (4) Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations. (5) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue by geographical area: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2023 | | 2022 | | 2023 | | 2022 | Revenue(1): | | | | | | | | | U.S. | $ | 5,531.4 | | | $ | 3,934.8 | | | $ | 9,967.6 | | | $ | 9,109.4 | | | Europe | 1,177.6 | | | 1,101.1 | | | 2,268.5 | | | 2,168.4 | | | Japan | 455.6 | | | 454.4 | | | 842.8 | | | 864.6 | | | China | 399.0 | | | 352.1 | | | 771.7 | | | 758.5 | | | Other foreign countries | 748.5 | | | 645.7 | | | 1,421.5 | | | 1,397.2 | | | Revenue | $ | 8,312.1 | | | $ | 6,488.0 | | | $ | 15,272.1 | | | $ | 14,298.0 | |
Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer or other party.
|